Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Neuroscience Right
  3. Kisunla (donanemab-azbt) injection, for intravenous infusion Right
  4. How does Kisunla™ (donanemab-azbt) work?
Search Kisunla™ (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Kisunla ™ (donanemab-azbt) injection, for intravenous infusion

350 mg/20 mL (17.5 mg/mL)

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How does Kisunla™ (donanemab-azbt) work?

Kisunla (donanemab) is a humanized immunoglobulin G1 monoclonal antibody directed against N3pG amyloid beta that is localized to deposited amyloid plaque in patients with Alzheimer's disease.

US_cFAQ_DON100A_MOA_ESAD_ON
US_cFAQ_DON100A_MOA_ESAD_ONen-US

See important safety information, including boxed warning, in the attached prescribing information.

Mechanism of Action of Donanemab

The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer’s disease (AD).1-4

Donanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that

  • is directed against the insoluble N-truncated terminal, third amino acid, pyroglutamate formation (N3pG) amyloid beta epitope that is localized to deposited amyloid plaque in patients with Alzheimer's disease,5-7 and
  • removes existing cerebral amyloid plaque through microglial-mediated phagocytosis.5,7,8

Donanemab reduced amyloid beta plaques in a dose- and time-dependent manner compared with placebo, as measured by amyloid positron emission tomography.1

See here for a video illustrating how donanemab works in early symptomatic AD. 

Enclosed Prescribing Information

KISUNLA™ (donanemab-azbt) injection, for intravenous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

2Raskin J, Cummings J, Hardy J, et al. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res. 2015;12(8):712-22. http://dx.doi.org/10.2174/1567205012666150701103107

3Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329-344. https://doi.org/10.1056/NEJMra0909142

4Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1-13. http://dx.doi.org/10.1016/j.jalz.2011.10.007

5DeMattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76(5):908-920. http://dx.doi.org/10.1016/j.neuron.2012.10.029

6Mintun MA, Lo AC, Evans CD, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691-1704. https://doi.org/10.1056/NEJMoa2100708

7Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. https://doi.org/10.1001/jama.2023.13239

8Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: January 02, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly